PurCell Bio Inc.

Startup

PurCell Bio has identified a major roadblock to cell-based technology, and we are addressing it by developing and marketing next gen Cell Culture systems to support the tremendous biotechnology advances of the 21st century.   PurSystems eliminate animal origin components, along with the eight known pathogens animal components may carry to end users.  This enables good science to proceed to clinic or market by eliminating the potential for bad outcomes posed by pathogens in animal derived media ingredients. Each PurSystem is meticulously designed and optimized for a single cell type, and produces more cells than its “serum free”, “xeno free” or “chemically defined” counterparts with healthier morphology.   This platform will support the amazing therapies and cell-based products that currently await FDA approval, including a cure for muscular Dystrophy (U of DE), safe, targeted gene therapy (numerous), cures for cystic fibrosis and other genetic disorders including enzyme disorders and diabetes.   Cells grown without exposure to animal derived components do not require testing for animal derived disease, and do not have epigenetic characteristics effected by exposure to animal components, toxins, drugs and pathogens.  This makes them easily acceptable to FDA and clinical trials, bringing them safely and efficiently to the patients and consumers who need them.

PurCell Bio is currently marketing our first two products, FibroPur media system for fibroblasts, and StemPur media system for stem cells.   We are seeking up to $5M in investment to support marketing efforts and development of our next two media systems, HEKPur and CHOPur, as well as our AOF reprogramming kits for stem cell production.  We have two large collaborations in negotiations, HiMedia Labs in India, and Mitsubishi International Food Ingredients (MIFI) in Japan, as well as two GMP manufacturing partners here in the US.  We are on the verge of entry into this $54B market, and we anticipate becoming the gold standard for each cell type as we introduce our advanced, clean and reliable platforms to the industries that need them.

PurCell Bio Inc. is a cutting-edge biotechnology company focused on revolutionizing the field of precision medicine and healthcare through the introduction of next gen Cell Culture systems to support the tremendous biotechnology advances of the 21st century.   With a strong emphasis on research and development, PurCell Bio is dedicated to advancing personalized healthcare solutions for patients, healthcare providers, and industry partners, through improvement of the foundation of cell-based bioproduction, the media environment.

PurCell Bio's media systems eliminate animal origin components, along with the eight known pathogens animal components may carry to end users.  This enables good science to proceed to clinic or market by eliminating the potential for bad outcomes posed by pathogens in animal derived media ingredients.  Each PurSystem is meticulously designed and optimized for a single cell type, and produces more cells than competitors with healthier morphology.   This platform will support the amazing therapies and cell-based products that currently await FDA approval or clinical trials, including a cure for muscular Dystrophy (U of DE), safe, targeted gene therapy (numerous), cures for cystic fibrosis and other genetic disorders including enzyme disorders and diabetes.   Cells grown without exposure to animal derived components do not require testing for animal-borne disease, and do not have epigenetic characteristics effected by exposure to animal components, toxins, drugs and pathogens.  This makes them easily acceptable to FDA and clinical trials, bringing them safely and efficiently to the patients and consumers who need them.   Our team of experts is committed to developing media systems for more cell types, to enable more accurate diagnoses, targeted treatments, and improved patient outcomes. By harnessing the latest advancements in technology, we strive to unlock the full potential of precision medicine and transform the way drugs are developed and tested as well.

Through strategic collaborations and partnerships with leading industry players, academic institutions, and healthcare organizations, PurCell Bio is at the forefront of driving innovation in the life sciences sector. Our multidisciplinary approach combines expertise in bioinformatics, genomics, metabolomics, cell biology, systems biology and AI to accelerate the development of next-generation platforms for tomorowws diagnostic tools, therapies, cures, and even lab meat.

As we showcase our groundbreaking technologies and solutions at BioTechX USA 2025, we invite attendees to learn more about how PurCell Bio is shaping the future of precision medicine and bioproduction for research and healthcare. Join us in our mission to harness the power of knowledge, creativity, AI, and innovation to revolutionize healthcare options, and improve patient outcomes worldwide.

website